# Anixa Biosciences, Inc. (ANIX)

> Anixa Biosciences, Inc. (ANIX) trades at $2.44 (-6.15%) as of 7:30:05 PM EST on Nov 20, 2026, -12.23% over the past month. Market cap is $84.82M, with 8.4 days to cover in short interest.

Canonical: https://massive.com/quote/anix
Data as of: 2026-11-21T00:30:05.198Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.44** -0.16 (-6.15%)
As of 7:30:05 PM EST on Nov 20, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Anixa Biosciences, Inc. (ANIX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -6.15% |
| 1W | -6.87% |
| 1M | -12.23% |
| YTD | -21.79% |
| 1Y | -43.91% |
| 52-wk range | $2.32 – $5.46 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for ANIX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.40 – $2.59 |
| Open | $2.55 |
| Prev close | $2.60 |
| Volume | 355.05K |
| Market cap | $84.82M |
| Shares out | 34.76M |

## Valuation and profitability ratios

Valuation and profitability ratios for Anixa Biosciences, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 5.86 |
| P/FCF | — |
| ROE | -71.7% |
| ROA | -68.9% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Anixa Biosciences, Inc. (ANIX) insider trading](https://massive.com/quote/anix/insider-trading.md): open-market Form 4 buys and sells by Anixa Biosciences, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Anixa Biosciences, Inc. has disclosed to the SEC on Form 8-K.

- Mar 11, 2026 · Annual meeting results
  “On March 10, 2026, Anixa Biosciences, Inc. (the "Company") completed its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company's executive compensation, and (iii) ratified the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026.”
- Feb 9, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol.”
- Dec 12, 2025 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “the Company and The Cleveland Clinic Foundation presented final data from the Phase 1 clinical trial of its investigational breast cancer vaccine.”
- Mar 21, 2025 · Annual meeting results
  “On March 20, 2025, Anixa Biosciences, Inc. (the "Company") completed its 2025 annual meeting of stockholders (the "Annual Meeting")... At the Annual Meeting, the Company's stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company's executive compensation, (iii) ratified the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025 and (iv) selected, on a non-binding, advisory basis, one year as the frequency of conducting future stockholder advisory votes on named executive officer compensation.”
- Nov 8, 2024 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “the Company and The Cleveland Clinic Foundation presented new, updated positive data for the Phase 1 study of its breast cancer vaccine”

## ANIX short interest

How heavily ANIX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.4 |
| Short interest | 1.63M |
| Avg volume | 193.79K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ANIX news

The latest news and headlines about Anixa Biosciences, Inc. (ANIX).

- [Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology](https://www.benzinga.com/pressreleases/26/04/n52127028/anixa-biosciences-announces-issuance-of-mexican-patent-covering-breast-cancer-vaccine-technology?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 29, 2026 · positive sentiment
- [Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology](https://www.benzinga.com/pressreleases/26/03/n51124962/anixa-biosciences-receives-notice-of-allowance-from-korean-ministry-of-intellectual-property-moip-?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 9, 2026 · positive sentiment
- [Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals](https://www.benzinga.com/pressreleases/25/09/n47697412/cancer-immunotherapy-surge-drives-258b-market-as-fda-accelerates-approvals) · Benzinga · Sep 16, 2025 · positive sentiment
- [Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024](https://www.benzinga.com/pressreleases/24/10/n41651578/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13-14-2024) · Benzinga · Oct 31, 2024 · positive sentiment
- [EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy - Benzinga](https://www.benzinga.com/general/biotech/24/07/39903448/exclusive-fda-approves-anixa-biosciences-individual-patient-trial-application-for-ovarian-cancer-) · Benzinga · Jul 23, 2024 · positive sentiment

## About Anixa Biosciences, Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Listed | Oct 7, 1983 |

[Company website](https://www.anixa.com)

## FAQ

### What is the Anixa Biosciences, Inc. (ANIX) stock price today?

Anixa Biosciences, Inc. (ANIX) is trading at $2.44 (-6.15% on the day) as of 7:30:05 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Anixa Biosciences, Inc.?

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other.

### What is the short interest in ANIX?

As of Oct 30, 2026, ANIX has 1.63M shares short and 8.4 days to cover.

### What exchange is ANIX listed on?

Anixa Biosciences, Inc. (ANIX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ANIX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ANIX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Anixa Biosciences, Inc. (ANIX) insider trading](https://massive.com/quote/anix/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
